Progress of LEU TechneLite® Generators and Xenon 133 Supply

Ira Goldman
Senior Director, Global Strategic Supply and Government Relations

Kathy McFadden
Senior Director, Commercial Sales and Operations

DOE Mo-99 Topical Meeting
September 12, 2016
St. Louis, MO
Content

• LEU TechneLite® Manufacture
• LEU Supply Chain
• TechneLite® Commercial Progress
• Xe-133
Lantheus Medical Imaging (LMI)

| Company Overview | • A global leader in innovative diagnostic medical imaging agents  
|                  | • Pharmaceutical imaging agents used to diagnose coronary artery disease, congestive heart failure, stroke, lung disease and other diseases |
| Headquarters     | • N. Billerica, Massachusetts |
| Offices          | • U.S., Canada and Puerto Rico |
| Commercial Products | • 9 |
| Development Pipeline | • Three next-generation product candidates that use Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) |
Lantheus Medical Imaging
LEU Leadership

- **FIRST** – to receive FDA approval for LEU Mo-99 in North America:
  - ANSTO: May 2011
  - NTP: September 2010

- **FIRST** – to commercially sell a generator made with only LEU Mo-99 (December 2010)

- **FIRST** – to have LEU Mo-99 as a routine part of blended Tc-99m production (May 2011)

- **FIRST** – to commercially manufacture and regularly distribute CMS non-HEU (LEU) incremental add-on HOPPS payment compliant generators (beginning Jan. 7, 2013)
Lantheus Medical Imaging adds the innovative LEU Technetium TC-99m Generator to our Nuclear Medicine Portfolio

Available NOW!

Technetium and corporate logo display are registered trademarks of Lantheus Medical Imaging, Inc.
©2013 Lantheus Medical Imaging, Inc. All rights reserved. January 2013
LEU Supply

• Dedicated, weekly LEU TechneLite® generator runs 2013-16 (89.6%)
  • 2013 – 46 weeks
  • 2014 – 42 weeks
  • 2015 – 50 weeks
  • 2016 – 25 weeks (through H1)

• LEU Mo-99 as proportion of total LMI purchased Mo-99:
  2013: 29%  2014: 32%  2015: 41%  2016 (est.): 50%

• ANSTO capacity increase to 2250 Ci/week in existing plant approved August 2016

• ANSTO ANM project (3500 Ci/week) commissioning 1Q2017; validation runs planned 1H2017 followed by FDA/HC filings

• IRE LEU conversion: validation runs late 2016; FDA/HC filings 1H2017

• Lantheus currently anticipates full transition to LEU in 2HQ2017
LEU TechneLite® generators shipped activity

LEU Activity Shipped from LMI

LEU TechneLite® Commercial Progress

• Misperceptions and misunderstandings continue in the market about LEU availability and reliability, CMS add-on payment, etc.
  • concern about CMS audit and fines

• Lantheus interacting with customers to promote uptake of LEU generators
  – Adoption has increased at Rx level beginning of year
    • leveled off middle of year
  – CMS data demonstrates steadily rising claims, though still small
  – Some Private Payers are reimbursing use of LEU
    • need reimbursement policy for all covered individuals

• Lantheus continues to provide information to increase LEU knowledge at hospitals (i.e. August 2014 webinar, 2015 webinar)

• Continue to assess LEU supply chain ability to service additional or different days of LEU TechneLite® manufacture
LEU TechneLite®

• Lantheus LEU Webinar:
  – Provides a Nuclear Pharmacy’s 2-year experience
    • Implementation into pharmacy operation
      – Operation changes
      – System changes
    • Education of End Users in market
    • Delivery of LEU doses to End Users
  – Provides an End Users’ experience
    • Implementation into operation
      – Operation changes
      – System changes
    • Reimbursement process

- NOT AS DIFFICULT AS OFTEN PORTRAYED

• UPPI “LEU Walk” continues
  – >33 pharmacies purchasing
  – many are 100% LEU
Xenon Xe 133 Gas (Xenon 133)

- Xenon 133 used in U.S. for pulmonary imaging
- Lantheus announced new strategic agreement with IRE for future supply of Xenon 133 gas on January 21, 2015
  - IRE provides unprocessed radiochemical Xenon 133 to Lantheus for processing and finishing
- FDA approval received June 10, 2016
- First commercial shipment June 30, 2016
- Currently increasing shipments from IRE and decreasing from Nordion; all IRE beginning in November
- Pursuing diversification options
- IRE LEU-based Xenon-133 project in early stage
Conclusions

- Lantheus has taken a leadership role in use of LEU Mo-99 in its TechneLite® generator supply chain
- LEU TechneLite® generators poised for significant increase in 2017 with projected all-LEU Mo-99 supply
- LEU key to enhanced global nuclear security and creates foundation for more secure, reliable future supply of Mo-99
- Lantheus and IRE have secured Xenon-133 supply

TechneLite® and corporate logo display are registered trademarks of Lantheus Medical Imaging, Inc.
Thank you

Questions?